Last reviewed · How we verify
Herpes simplex virus containing gD-Alum
At a glance
| Generic name | Herpes simplex virus containing gD-Alum |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Herpes simplex virus containing gD-Alum CI brief — competitive landscape report
- Herpes simplex virus containing gD-Alum updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI